Reforms To Increase Regulation Within The Pharmaceutical Industry

BMI View: Dialogue between firms, regulators and payers will become more common as the communication of product value becomes increasingly important. Regulatory agencies that make reimbursement decisions are becoming increasingly tough (in order to contain costs), while the competitive environment has changed - the pool of generic drugs is growing, the pool of patented drugs is falling, the number of mass market products are falling and the number of niche products is rising. Moreover, regulatory hurdles have increased and payers have implemented reference pricing systems, health technology assessments (HTAs), budget caps and copayment and risk-sharing systems. The audience to

To read the full article, please choose one of the following options: